Research programme: anticancer antibodies - Attenuon/Kirin Brewery
Latest Information Update: 11 Jul 2007
At a glance
- Originator Attenuon LLC; Kirin Brewery
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Feb 2004 Preclinical trials in Cancer in USA (unspecified route)